KBC Group NV Purchases 600 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

KBC Group NV boosted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 89.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,273 shares of the specialty pharmaceutical company’s stock after buying an additional 600 shares during the period. KBC Group NV’s holdings in ANI Pharmaceuticals were worth $70,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Thrivent Financial for Lutherans grew its holdings in shares of ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares in the last quarter. Louisiana State Employees Retirement System lifted its position in ANI Pharmaceuticals by 3.9% during the third quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock valued at $477,000 after purchasing an additional 300 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in ANI Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $684,000 after buying an additional 310 shares in the last quarter. New York State Teachers Retirement System increased its holdings in shares of ANI Pharmaceuticals by 1.7% in the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock worth $1,439,000 after buying an additional 394 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its position in shares of ANI Pharmaceuticals by 5.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock valued at $564,000 after buying an additional 464 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. The trade was a 8.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 42,381 shares of company stock worth $2,441,556. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Down 1.6 %

Shares of ANI Pharmaceuticals stock opened at $59.59 on Tuesday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The company’s 50 day moving average price is $56.74 and its 200-day moving average price is $58.40. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -108.35 and a beta of 0.74.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company’s revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.05 EPS. Equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective on the stock. Truist Financial upped their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 5th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.